Tokushima University / Educator and Researcher Directory --- Tomonari, Tetsu

Field of Study

Subject of Study

Book / Paper

Book:

1.	Tetsu Tomonari : 実臨床におけるカボザンチニブの初期使用経験(第6章日常臨床下におけるカボザンチニブの治療成績)., Arcmedium, Tokyo, Mar. 2022.
2.	Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌におけるレンバチニブの治療成績., Arcmedium, Jan. 2019.

Academic Paper (Judged Full Paper):

1.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, shota Fujimoto, Tomoyuki Kawaguchi, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study., Eur J Clin Invest, Vol.Online ahead of print., 2024. (Link to Publication Site) ● Publication site (DOI): 10.1111/eci.14221. (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38634705 ● Search Scopus @ Elsevier (PMID): 38634705 ● Search Scopus @ Elsevier (DOI): 10.1111/eci.14221. (DOI: 10.1111/eci.14221., PubMed: 38634705)
2.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study., Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024. (Summary) Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged ≥50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged ≥50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16530 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514 ● Search Scopus @ Elsevier (PMID): 38419514 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530 (DOI: 10.1111/jgh.16530, PubMed: 38419514)
3.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study., Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024. (Summary) The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged ≥ 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged ≥ 50 years is important for gallstone prevention. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16483 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880 ● Search Scopus @ Elsevier (PMID): 38212880 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483 (DOI: 10.1111/jgh.16483, PubMed: 38212880)
4.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Shigekazu Sugino, Jun Suzuki, Masaki Fujishima, Eri Okumura, Hideo Takekoshi, Osamu Uehara, Shintaro Sugita, Yoshihiro Abiko, Tetsu Tomonari, Hironori Tanaka, Hidekatsu Takeda and Tetsuji Takayama : Acanthopanax senticosus ameliorates steatohepatitis through HNF4 alpha pathway activation in mice., Scientific Reports, Vol.14, No.1, 110, 2024. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-50625-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38167633 ● Search Scopus @ Elsevier (PMID): 38167633 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-50625-z (DOI: 10.1038/s41598-023-50625-z, PubMed: 38167633)
5.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Tsutomu Masaki and Tetsuji Takayama : Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma., Cancers, Vol.15, No.21, 5221, 2023. (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers15215221 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/cancers15215221 (DOI: 10.3390/cancers15215221)
6.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study., Clinical Nutrition, Vol.42, No.5, 810-816, 2023. (Summary) The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676-1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753-1.439, p = 0.808); the OR for women who drank 140-279.9 g/week was 2.135 (95% CI, 1.158-3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD (p < 0.005). Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD. (Tokushima University Institutional Repository) ● Metadata: 118599 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clnu.2023.03.020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37043935 ● Search Scopus @ Elsevier (PMID): 37043935 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clnu.2023.03.020 (Tokushima University Institutional Repository: 118599, DOI: 10.1016/j.clnu.2023.03.020, PubMed: 37043935)
7.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments., Clinical Journal of Gastroenterology, Vol.16, No.3, 438-443, 2023. (Summary) The efficacy of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN-TACE) has been reported, but its effect on unresectable hepatocellular carcinoma (HCC) refractory to LEN therapy has not been demonstrated. We report a case of HCC refractory to multiple molecular-targeted agents (MTA) treatments, including LEN, that was successfully treated with LEN-TACE. A 59-year-old man was referred to our department with multiple HCCs and a background of hepatitis B virus infection. TACE was the initial treatment. However, he was determined to be TACE-refractory, and multitargeted therapy was initiated. LEN was started at 12 mg/day but resulted in progressive disease (PD) after 13 months of the administration. The response to second-line sorafenib was PD after 2 months. Third-line therapy with atezolizumab + bevacizumab was stopped after one course because of an immune-related adverse event (i.e., dermatitis). The response to fourth-line regorafenib was PD at 2 months, and the response to fifth-line cabozantinib was PD after 6 months. The efficacy of LEN-TACE was recently reported; therefore, we decided to attempt LEN-TACE therapy as a salvage line. After obtaining the patient's consent to repeat LEN and TACE, treatment was initiated. The tumor markers levels markedly reduced after LEN-TACE therapy. After three additional TACE treatments with continued LEN administration, the tumor marker levels normalized, and complete response was determined based on RECIST guidelines. LEN-TACE therapy may effectively treat unresectable advanced HCC in the LEN-rechallenge setting and may be a treatment option as a last-line therapeutic option. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-023-01777-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36856957 ● Search Scopus @ Elsevier (PMID): 36856957 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-023-01777-y (DOI: 10.1007/s12328-023-01777-y, PubMed: 36856957)
8.	Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama : Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma., Hepatology Research, Vol.53, No.2, 172-178, 2023. (Summary) Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modifications of CAB. We analyzed the clinical outcomes of CAB in uHCC and compared treatment outcomes between the full- and reduced-dose groups. This multicenter, observational study included patients with uHCC who were treated with CAB from March 2021 to April 2022. Patient characteristics, efficacy, and safety were compared between the full- and reduced-dose groups. Twenty-six patients from eight institutes were analyzed. Cabozantinib was administered as a third-line or later treatment in 25 (96.2%) patients and postimmunotherapy in 21 (80.5%) patients. There were 15 patients in the full-dose group (60 mg CAB) and 11 in the reduced-dose group (40 or 20 mg CAB). The objective response rate (ORR) and disease control rate (DCR) were not significantly different between the two groups. The ORR was 6.7% for the full-dose group and 9.1% for the reduced-dose group, and the DCR was 53.4% and 81.8%, respectively. Progression-free survival analysis showed no significant differences between the two groups. The incidence of decreased appetite, fatigue, and diarrhea, and the rate of discontinuation and dose reduction, was significantly higher in the full-dose group. Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13845 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36214071 ● Search Scopus @ Elsevier (PMID): 36214071 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13845 (DOI: 10.1111/hepr.13845, PubMed: 36214071)
9.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Akihiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki and Tetsuji Takayama : Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve., Cancer Medicine, Vol.12, No.3, 2646-2657, 2023. (Summary) We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC). In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group. In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a. (Tokushima University Institutional Repository) ● Metadata: 117987 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.5145 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35964253 ● Search Scopus @ Elsevier (PMID): 35964253 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.5145 (Tokushima University Institutional Repository: 117987, DOI: 10.1002/cam4.5145, PubMed: 35964253)
10.	Yasushi Sato, Yasuyuki Okada, Yasuteru Fujino, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Hironori Tanaka, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Masahiro Sogabe and Tetsuji Takayama : Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 154-159, 2023. (Summary) In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine's current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n=30), colorectal (n=25), biliary tract (n=15), gastric (n=11), and hepatocellular carcinoma (n=8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n=1), colorectal (n=3), and small bowel cancers (n=1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n=40) and the inability to participate in clinical trials (n=10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs. J. Med. Invest. 70 : 154-159, February, 2023. (Keyword) Humans / Gastrointestinal Neoplasms / Neoplasms / Colorectal Neoplasms / Genomics / Hospitals / Japan (Tokushima University Institutional Repository) ● Metadata: 118346 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.154 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164713 ● Search Scopus @ Elsevier (PMID): 37164713 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.154 (Tokushima University Institutional Repository: 118346, DOI: 10.2152/jmi.70.154, PubMed: 37164713)
11.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study., Nutrients, Vol.14, No.22, 4760, 2022. (Summary) The influence of changes in alcohol consumption on erosive esophagitis (EE) development in both sexes is unclear. This observational study investigated sex differences in the influence of alcohol consumption on EE development, and included 2582 patients without EE at baseline from 13,448 patients who underwent >2 health check-ups over >1 year. The rates of non-drinkers who started drinking, and drinkers who abstained from drinking, who increased, and who decreased their weekly alcohol consumption were 7.2%, 9.7%, 14.7%, and 24.1% and 7.3%, 17.8%, 12.8%, and 39.0% in men and women, respectively. In the final cohort, 211/1405 (15.0%) men and 79/1177 (6.7%) women newly developed EE. The odds ratio (OR) for drinking in EE development was 1.252 (95% confidence interval (CI), 0.907-1.726) among men and 1.078 (95% CI, 0.666-1.747) among women. Among men aged <50 years, the OR for drinking ≥70 g/week in EE development was 2.825 (95% CI, 1.427-5.592), whereas among women, the OR for drinking ≥140 g/week in EE development was 3.248 (95% CI, 1.646-6.410). Among participants aged <50 years, the OR for daily drinking in EE development was 2.692 (95% CI, 1.298-5.586) among men and 4.030 (95% CI, 1.404-11.57) among women. The influence of alcohol consumption on EE development differed between the sexes. We recommend no alcohol consumption for individuals aged <50 years to avoid EE development. Daily drinkers should be assessed for EE development. (Keyword) Humans / Male / Female / Longitudinal Studies / Alcohol Drinking / Esophagitis / Sexual Behavior / Cohort Studies / Peptic Ulcer (Tokushima University Institutional Repository) ● Metadata: 118071 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu14224760 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36432447 ● Search Scopus @ Elsevier (PMID): 36432447 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14224760 (Tokushima University Institutional Repository: 118071, DOI: 10.3390/nu14224760, PubMed: 36432447)
12.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Kaizoh Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females., Scientific Reports, Vol.12, No.1, 16048, 2022. (Summary) The clinical difference between nonalcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) between the two sexes is unclear. This study aimed to determine the influences of alcohol consumption and qualitative abdominal fat between male and female patients with NAFLD and MAFLD. This cross-sectional study examined 11,766 participants who underwent health check-ups comparing lifestyle habits, biochemical features, and noninvasive liver fibrosis scores, between non-MAFLD and MAFLD groups. Furthermore, differences in alcohol consumption and qualitative abdominal fat were examined between male and female patients with NAFLD and MAFLD. The prevalence of metabolic dysregulation, ratio of visceral fat area to subcutaneous fat area, and noninvasive liver fibrosis scores were significantly higher in male patients with MAFLD than in those with NAFLD (p < 0.05), but these were not significantly different in female patients. Among male patients with an alcohol consumption of > 70 g/week, several noninvasive liver fibrosis scores were significantly higher in the MAFLD group than in the NAFLD group (all p < 0.05). The influences of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD were different between sexes. The development of liver fibrosis should be considered in male patients with MAFLD who exceed mild drinking. (Keyword) Alcohol Drinking / Cross-Sectional Studies / Female / Humans / Intra-Abdominal Fat / Liver Cirrhosis / Male / Non-alcoholic Fatty Liver Disease (Tokushima University Institutional Repository) ● Metadata: 117853 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-20124-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36163355 ● Search Scopus @ Elsevier (PMID): 36163355 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-20124-8 (Tokushima University Institutional Repository: 117853, DOI: 10.1038/s41598-022-20124-8, PubMed: 36163355)
13.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma., JGH Open, Vol.5, No.11, 1275-1283, 2021. (Tokushima University Institutional Repository) ● Metadata: 116741 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12663 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.12663 (Tokushima University Institutional Repository: 116741, DOI: 10.1002/jgh3.12663)
14.	Masanori Takehara, Hiroshi Miyamoto, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Koichi Okamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma., Case Reports in Gastroenterology, Vol.15, No.3, 910-918, 2021. (Summary) A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis. (Tokushima University Institutional Repository) ● Metadata: 116721 (Link to Publication Site) ● Publication site (DOI): 10.1159/000519211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34720843 ● Summary page in Scopus @ Elsevier: 2-s2.0-85117511057 (Tokushima University Institutional Repository: 116721, DOI: 10.1159/000519211, PubMed: 34720843, Elsevier: Scopus)
15.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi and Tetsuji Takayama : MiR-125b-5p is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma., Cancers, Vol.13, No.19, 4917, 2021. (Summary) The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression-findings similar to those for PLC/PRF5-R2-which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients. (Tokushima University Institutional Repository) ● Metadata: 116647 (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers13194917 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34638401 ● Search Scopus @ Elsevier (PMID): 34638401 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers13194917 (Tokushima University Institutional Repository: 116647, DOI: 10.3390/cancers13194917, PubMed: 34638401)
16.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Kaizoh Kagemoto, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study., Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, Vol.14, 1589-1600, 2021. (Tokushima University Institutional Repository) ● Metadata: 116294 (Link to Publication Site) ● Publication site (DOI): 10.2147/DMSO.S298326 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33883913 ● Summary page in Scopus @ Elsevier: 2-s2.0-85104815967 (Tokushima University Institutional Repository: 116294, DOI: 10.2147/DMSO.S298326, PubMed: 33883913, Elsevier: Scopus)
17.	Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama : Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis., Hepatology Research, Vol.51, No.4, 472-481, 2021. (Summary) The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first-line treatment for unresectable hepatocellular carcinoma (u-HCC) remains debatable. Using propensity score matching, this study compares the outcomes of SOR and LEN in the molecular-targeted agent (MTA) sequential treatment of u-HCC patients. This retrospective, multicenter, observational study recruited 137 u-HCC patients who underwent primary treatment with LEN (n = 52) or SOR (n = 85) between June 2017 and June 2020 after regorafenib was approved as the secondary treatment for u-HCC. Propensity score matching was used to reduce confounding, resulting in the selection of 104 patients (n = 52 for the SOR and LEN cohorts). The median overall survival was 21.8 months for LEN and 20.4 months for SOR. LEN exhibited significantly greater therapeutic efficacy as compared to SOR (objective response rate: 3.8% [SOR] vs. 42.3% [LEN], P <0.01; progression-free survival: 10 months [LEN] vs. 5.1 months [SOR], P <0.01). No significant intergroup differences were noted in the rate of transition to secondary MTA treatments (SOR: 58.7%; LEN: 48.4%), adverse events (SOR: 86%; LEN: 95%), and maintenance of the Child-Pugh (CP) score during treatment. Compared to non-MTA treatments, secondary MTA treatment achieved a greater improvement in survival ( 4.3 months vs. 2.8 months, P=0.0047). Multivariate analysis demonstrated that the CP score (P <0.01) and alpha-fetoprotein level (P <0.01) were independent prognostic factors. Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13597 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33238074 ● Search Scopus @ Elsevier (PMID): 33238074 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13597 (DOI: 10.1111/hepr.13597, PubMed: 33238074)
18.	Hironori Tanaka, Yoshihito Saijyo, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi, Shusuke Yagi, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, Masataka Sata and Tetsuji Takayama : An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration, Internal Medicine, Vol.60, No.12, 1839-1845, 2021. (Summary) A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved. (Tokushima University Institutional Repository) ● Metadata: 116336 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.5914-20 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456037 ● Search Scopus @ Elsevier (PMID): 33456037 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.5914-20 (Tokushima University Institutional Repository: 116336, DOI: 10.2169/internalmedicine.5914-20, PubMed: 33456037)
19.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports., Medicine, Vol.99, No.42, e22782, 2020. (Summary) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (Keyword) Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins (Tokushima University Institutional Repository) ● Metadata: 116240 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000022782 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748 ● Search Scopus @ Elsevier (PMID): 33080748 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782 (Tokushima University Institutional Repository: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748)
20.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Masanori Takehara, Kaizoh Kagemoto, Jun Okazaki, Yoshifumi Kida, Akihiro Hirao, Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Nakasono and Tetsuji Takayama : Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome., PLoS ONE, Vol.15, No.8, e0238388, 2020. (Summary) The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine aminotransferase (ALT) levels than in those having NAFLD with normal ALT levels. To measure the differences in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with and without NAFLD having elevation of ALT. Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met the selection criteria. We measured differences in clinical factors for NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS. The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progressively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the Non-MS group, there were significant differences between subjects with and without NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid, aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group, there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT. There were significant differences in levels of metabolites of nicotinamide, inosine, and acetyl-L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all p <0.05). Although NAFLD having elevation of ALT is important for development of NAFLD, differences in factors associated with NAFLD having elevation of ALT at various stages of MS should be considered. Additionally, several metabolites may play roles in the identification of risk for NAFLD in individuals with MS. (Tokushima University Institutional Repository) ● Metadata: 115614 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0238388 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32866186 ● Search Scopus @ Elsevier (PMID): 32866186 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0238388 (Tokushima University Institutional Repository: 115614, DOI: 10.1371/journal.pone.0238388, PubMed: 32866186)
21.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma, JGH Open, Vol.4, No.6, 1135-1139, 2020. (Summary) Abstract Background and Aim Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN. Methods (Patients) and Results A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3 (Tokushima University Institutional Repository) ● Metadata: 115923 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33319048 ● Summary page in Scopus @ Elsevier: 2-s2.0-85089378719 (Tokushima University Institutional Repository: 115923, DOI: 10.1002/jgh3.12408, PubMed: 33319048, Elsevier: Scopus)
22.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
23.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Yasuteru Fujino, Yasuhiro Mitsui, Akihiro Hirao, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Harumi Kagiwada, Masashi Kitazawa, Kazuhiro Fukui, Ktsuhisa Horimoto and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array., Oncotarget, Vol.11, No.26, 2531-2542, 2020. (Summary) The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group ( < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR. (Tokushima University Institutional Repository) ● Metadata: 116246 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27640 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32655838 ● Search Scopus @ Elsevier (PMID): 32655838 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27640 (Tokushima University Institutional Repository: 116246, DOI: 10.18632/oncotarget.27640, PubMed: 32655838)
24.	Toshiya Okahisa, Masahiro Sogabe, Tadahiko Nakagawa, Kumiko Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Akira Takahashi, Yohsuke Kinouchi, Junji Nishioka, Naoki Igata, Hiroaki Yanagawa, takatoshi Komatsu, Yoshiaki Ohnishi, Masashi Fukuhara, Masashi Ishikawa, Hiroshi Shibata, Hirohiko Shinomiya, Masahiko Nakasono, Fumiko Kishi, Keiko Komai, Yayoi Tatsuki, Toru Murashima, Yoshihiro Deguchi, Hiroshi Aramaki, Hideyuki Fukumitsu and Tetsuji Takayama : Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy., Artificial Organs, Vol.44, No.8, 856-872, 2020. (Summary) Cell-free and concentrated ascites reinfusion therapy (CART) is an effective therapy for refractory ascites. However, CART is difficult to perform as ascites filtration and concentration is a complicated procedure. Moreover, the procedure requires the constant assistance of a clinical engineer or/and the use of an expensive equipment for the multi-purpose blood processing. Therefore, we developed a CART specialized equipment (mobility CART [M-CART]) that could be used safely with various safety measures and automatic functions such as automatic washing of clogged filtration filter and self-regulation of the concentration ratio. Downsizing, lightning of the weight, and automatic processing in M-CART required the use of newly developed multi-ring-type roller pump units. This equipment was approved under Japanese regulations in 2018. In performing 41 sessions of CART (for malignant ascites, 22 sessions; and hepatic ascites, 19 sessions) using this equipment in 17 patients, no serious adverse event occurred. An average of 4494 g of ascites was collected and the total amount of ascites was processed in all the sessions without any trouble. The mean weight of the processed ascites was 560 g and the mean concentration ratio was 8.0. The ascites were processed at a flow rate of 50 mL/min. The mean ascites processing time was 112.5 minutes and a 106.5-minutes (95.2%) ascites processing was performed automatically. The operator responded to alarms or support information 3.2 times on average (3.1 minutes, 2.1% of ascites processing time). Human errors related to ascites processing were detected by M-CART at 0.4 times per session on average and were appropriately addressed by the operator. The frequencies of automatic washing of clogged filtration filter and self-regulation of the concentration ratio were 31.7% and 53.7%, respectively. The mean recovery rates (recovery dose) of protein, albumin, and immunoglobulin G were 72.9%, 72.9%, and 71.2% (65.9 g, 34.9 g, and 13.2 g), respectively. Steroids were administered in 92.7% of the sessions to prevent fever and the mean increase in body temperature was 0.53°C. M-CART is a compact and lightweight automatic CART specialized equipment that can safely and easily process a large quantity of ascites without the constant assistance of an operator. (Tokushima University Institutional Repository) ● Metadata: 115878 (Link to Publication Site) ● Publication site (DOI): 10.1111/aor.13681 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32187379 ● Search Scopus @ Elsevier (PMID): 32187379 ● Search Scopus @ Elsevier (DOI): 10.1111/aor.13681 (Tokushima University Institutional Repository: 115878, DOI: 10.1111/aor.13681, PubMed: 32187379)
25.	Masahiro Sogabe, Toshiya Okahisa, Akira Fukuya, Kaizoh Kagemoto, Yasuyuki Okada, Yuka Adachi, Takeshi Kurihara, Toru Nii, Satoshi Teramae, Hironori Tanaka, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Masahiko Nakasono and Tetsuji Takayama : Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial., BMC Gastroenterology, Vol.20, No.1, 122, 2020. (Summary) Esophagogastroduodenoscopy (EGD) provides an indispensable and unambiguous inspection allowing the discovery upper gastrointestinal lesions. However, many patients are anxious about undergoing EGD. Few studies have investigated the influence on patients' vital signs and tolerance during EGD using subjective and objective assessments. This study was a prospective randomized controlled study that investigated the influence of audio and visual distraction on EGD. We randomly divided 289 subjects who underwent EGD into 4 groups (control group, audio group, visual group, combination group) and examined their vital signs, heart rate variability (HRV), psychological items, and acceptance of distraction. Pulse rate (PR) at post-distraction and post-EGD in the 3 distraction groups were significantly lower than those of control group (p < 0.001 and p < 0.01, respectively). Blood pressure (BP) during and post-EGD was significantly higher than that at pre-EGD in control group (p < 0.05), but no significant elevation of BP was observed during the latter half of EGD and post-EGD in the 3 distraction groups. BP at post-distraction improved significantly compared to pre-distraction in the 3 distraction groups (p < 0.05). There was a significant difference in the low-frequency (LF) power/ high-frequency (HF) power at post-distraction and post-EGD among the 4 groups (p < 0.001 and p < 0.001, respectively). The LF power/HF power at post-distraction and post-EGD in the 3 distraction groups was significantly lower than that in control group (p < 0.05). Several items of profile of mood states (POMS) and the impression of EGD at post-distraction improved significantly compared to those at pre-distraction among the 3 distraction groups (p < 0.05). Visual analog scale (VAS) of willingness for the next use of distraction in the 3 distraction groups was excellent because VAS was more than 70. Distractions effectively improved psychological factors, vital signs and some of HRV at pre and post-EGD. Distractions may suppress BP elevation during the latter half of EGD and lead to stability of HRV on EGD. This prospective trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000029637. Registered on 20 October 2017. (Tokushima University Institutional Repository) ● Metadata: 114760 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-020-01274-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32316918 ● Search Scopus @ Elsevier (PMID): 32316918 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-020-01274-3 (Tokushima University Institutional Repository: 114760, DOI: 10.1186/s12876-020-01274-3, PubMed: 32316918)
26.	Rie Harada, Masako Kimura, Yasushi Sato, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Naoki Muguruma, Hirohiko Shinomiya, Hirohito Honda, Issei Imoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism., BMC Gastroenterology, Vol.18, No.1, 24, 2018. (Summary) It has been reported that some single-nucleotide polymorphisms (SNPs) in lipid regulators such as apolipoproteins and cell surface molecules for hepatitis C virus (HCV) entry into hepatocytes are associated with HCV infection. However, it is unknown how HCV infection is affected by altered lipid metabolism resulting from the SNPs. We investigated the relationship between these SNPs and HCV infection status, and also analyzed the mechanism by which these SNPs mediate HCV infection via lipid metabolism alterations. Serum lipid and apolipoprotein profiles were tested in 158 HCV-positive and 220 HCV-negative subjects. We selected 22 SNPs in five lipid regulator genes which were related to HCV entry into hepatocytes and to lipid metabolism (APOA1, APOB, SR-B1, LDLR, and APOE), and their polymorphisms were analyzed using the PCR-sequence-specific oligonucleotide probe-Luminex method. An APOB N4311S (g.41553a > g) SNP, rs1042034, was significantly associated with HCV positivity; the HCV positivity rate for the minor allele AA genotype was significantly higher than for genotype AG + GG (P = 0.016). Other SNPs except for APOB P2712L SNP rs676210, which is in linkage disequilibrium with rs1042034, showed no significant difference in genotype distribution. The serum level of low density lipoprotein-cholesterol (LDL-C) in the genotype AA group was significantly lower than in the genotype non-AA group (P = 0.032), whereas the triglyceride (TG) level was significantly higher (P = 0.007). An APOB SNP, rs1042034, is closely associated with HCV infection through lipid metabolism alteration. The minor allele AA genotype might contribute to facilitating serum LDL uptake into hepatocytes via LDLR by modifying their affinity and interaction and may have an influence on HCV infection by their entry to the liver through the LDLR. (Tokushima University Institutional Repository) ● Metadata: 111808 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-018-0747-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29382324 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041353404 (Tokushima University Institutional Repository: 111808, DOI: 10.1186/s12876-018-0747-5, PubMed: 29382324, Elsevier: Scopus)
27.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Hiroshi Fukuno, Yoshihiko Miyamoto, Yasuyuki Okada, Jun Okazaki, Jinsei Miyoshi, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study., PLoS ONE, Vol.12, No.6, e0177925, 2017. (Summary) Nonalcoholic fatty liver disease (NAFLD) is known to be strongly associated with obesity, visceral fat, metabolic syndrome (MS), lifestyle, and lifestyle-related diseases in both males and females. However, the prevalence of NAFLD, MS, and clinical backgrounds is different between males and females. We conducted a cross-sectional study to examine the differing influence of lifestyle-related factors and visceral fat on fatty liver (FL) with elevation of liver enzymes between males and females with MS. We enrolled 42,134 persons who underwent a regular health check-up, and after excluding subjects who fulfilled excluding criteria, the remaining subjects were 2,110 persons with MS. We examined the differing influence of lifestyle-related factors and visceral fat on FL with elevation of alanine aminotransferase (ALT) (ALT elevation was defined as ALT level of ≥31 IU/l in the present study). The odds rations for FL with ALT elevation were as follows: WC, 1.83 (95% confidence interval (CI) 1.36-2.46); dyslipidemia, 1.89 (95% CI 1.34-2.68); hemoglobin A1c, 1.36 (95% CI 1.00-1.85); visceral fat type MS (V-type MS), 5.78 (95% CI 4.29-7.80); and light drinker, 0.56 (95% CI 0.41-0.78) in males with MS and BMI, 2.18 (95% CI 1.43-3.33); WC, 1.85 (95% CI 1.27-2.70); diastolic blood pressure, 1.69 (95% CI 1.16-2.45); triglyceride, 2.22 (95% CI 1.56-3.17); impaired glucose tolerance, 1.66 (95% CI 1.11-2.47); and V-type MS, 3.83 (95% CI 2.57-5.70) in females with MS. The prevalence of FL with ALT elevation and ALT was significantly higher in V-type MS than in the subcutaneous fat type MS in both males and females with MS (P < 0.001). Although V-type MS and WC is a common significant predictor of an increased prevalence of FL with ALT elevation in both males and females with MS, gender, lifestyle-related factors, and MS type in individuals with MS should be considered for the development of FL with ALT elevation. (Tokushima University Institutional Repository) ● Metadata: 112319 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0177925 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28574988 ● Summary page in Scopus @ Elsevier: 2-s2.0-85020298128 (Tokushima University Institutional Repository: 112319, DOI: 10.1371/journal.pone.0177925, PubMed: 28574988, Elsevier: Scopus)
28.	Tatsuya Taniguchi, Kazuhiro Kishi, Tadahiko Nakagawa, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Toshiya Okahisa, Naoki Muguruma, Mayumi Kajimoto, Ikuko Sagawa and Tetsuji Takayama : Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma., Digestion, Vol.95, No.3, 242-251, 2017. (Summary) Although des-gamma-carboxy prothrombin (DCP) is a well-known tumor marker for hepatocellular carcinoma (HCC), the mechanism of DCP production is unclear. This study aimed to investigate the mechanism how DCP is produced in HCC cells. Levels of mRNA and DCP were analyzed by real-time polymerase chain reaction and electro-chemiluminescence immunoassay respectively. Secreted alkaline phosphatase (SEAP) expression vectors including deletion mutants of the prothrombin gene promoter were constructed for reporter gene assay. The transcription factors bound to DNA fragments were analyzed by mass spectrometry. An electrophoretic mobility shift assay (EMSA) was performed using a biotin end-labeled DNA. The prothrombin mRNA levels in all 5 DCP producing cell lines were appreciably high. However, those in 2 DCP non-producing cell lines were below detectable levels. A SEAP vector with -2985 to +27 showed a very high transcription activity in DCP-producing Huh-1 cells. However, transcription abruptly decreased when the vector with -2955 to +27 was transfected, and then remained at the similar levels with larger deletion mutants, indicating the existence of a cis-element at -2985 to -2955 (31-bp). Mass spectrometry analysis identified the protein that bound to the 31-bp DNA as poly-(ADP-ribose) polymerase-1 (PARP-1). Knockdown of the PARP-1 gene by small interfering RNA in Huh-1 cells induced marked inhibition of prothrombin gene transcription. The EMSA clearly showed that PARP-1 specifically binds to the 31-bp DNA fragment in the prothrombin gene promoter. Our data suggest that PARP-1 activates prothrombin gene transcription and that the excessive prothrombin gene transcription induces DCP production in DCP-producing HCC cells. (Tokushima University Institutional Repository) ● Metadata: 110173 (Link to Publication Site) ● Publication site (DOI): 10.1159/000470837 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28384634 ● Search Scopus @ Elsevier (PMID): 28384634 ● Search Scopus @ Elsevier (DOI): 10.1159/000470837 (Tokushima University Institutional Repository: 110173, DOI: 10.1159/000470837, PubMed: 28384634)
29.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Hiroshi Fukuno, Masahiko Nakasono, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Tatsuya Taniguchi, Naoki Muguruma and Tetsuji Takayama : Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome., BMC Gastroenterology, Vol.16, No.1, 17, 2016. (Summary) Although heavy drinking is known to lead to liver injury, some recent studies have reported that light alcohol consumption (LAC) may play a protective role against fatty liver in the general population, and may even play a protective role against non-alcoholic fatty liver disease (NAFLD) in males with metabolic syndrome (MS). However, the association between LAC and fatty liver with liver enzyme elevation in females with MS is unclear. Participants of this study were 20,853 females who underwent a regular health check-up between April 2008 and March 2012 at our hospital. Enrolled subjects were 1141 females with MS, who underwent all necessary tests and drank less than 20 g/day of alcohol. We investigated the presence of fatty liver with liver enzyme elevation, defined in this study as alanine aminotransferase (ALT) levels ≧31 IU/I, and the association between LAC and fatty liver with ALT elevation. There was no significant difference in the prevalence of fatty liver and ALT between light drinkers and non-drinkers. The prevalence of individuals receiving a treatment for dyslipidemia and impaired glucose tolerance (IGT) was significantly lower in light drinkers than in non-drinkers. Body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), triglyceride (TG), uric acid (UA), IGT, and visceral fat type MS (V-type MS) were significant predictors of the prevalence of fatty liver with ALT elevation in logistic regression analysis. The odds ratio [OR] (95 % confidence interval [CI], p value) for fatty liver with ALT elevation were as follows: BMI, 2.181 (1.445-3.293, p <0.001); WC, 1.853 (1.280-2.684, p <0.01); DBP, 1.604 (1.120-2.298, p <0.05); TG, 2.202 (1.562-3.105, p <0.001); UA, 2.959 (1.537-5.698, p <0.01); IGT, 1.692 (1.143-2.506, p <0.01); and V-type MS, 3.708 (2.529-5.437, p <0.001). There was no significant difference in the prevalence of fatty liver with ALT elevation in females with MS between light drinkers and non-drinkers, suggesting that other factors such as BMI, WC, V-type MS, and lifestyle-related disease may be more important than LAC for the prevalence of fatty liver with ALT elevation. (Tokushima University Institutional Repository) ● Metadata: 114348 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-016-0431-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26892109 ● Search Scopus @ Elsevier (PMID): 26892109 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-016-0431-6 (Tokushima University Institutional Repository: 114348, DOI: 10.1186/s12876-016-0431-6, PubMed: 26892109)
30.	Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Shota Fujimoto, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma, Oncotarget, Vol.7, No.6, 7207-7215, 2016. (Summary) The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. Accordingly, we established sorafenib-resistant HCC cells and investigated the underlying mechanism of resistance to sorafenib. Sorafenib-resistant cell lines were established from the HCC cell line PLC/PRF5 by cultivation under continuous exposure to increasing concentration of sorafenib. The IC50 values of the 2 resistant clones PLC/PRF5-R1 and PLC-PRF5-R2 were 9.2±0.47 M (1.8-fold) and 25±5.1 M (4.6-fold) respectively, which were significantly higher than that of parental PLC/PRF5 cells (5.4±0.17 M) (p < 0.01 respectively), as determined by MTT assay. Western blot analysis of signal transduction-related proteins showed no significant differences in expression of AKT/pAKT, mTOR/pmTOR, or ERK/pERK between the 2 resistant clones versus parent cells, suggesting no activation of an alternative signal transduction pathway. Likewise, when expression of membrane transporter proteins was determined, there were no significant differences in expression levels of BSEP, MDR1, MRP2, BCRP, MRP4 and OCT1 between resistant clones and parent cells. However, the expression levels of MRP3 in the 2 resistant clones were significantly higher than that of parent cells. When MRP3 gene was knocked down by siRNA in PLC-PRF5-R2 cells, the sensitivity of the cells to sorafenib was restored. In the analysis of gene mutation, there was no mutation in the activation segment of Raf1 kinase in the resistant clones. Our data clearly demonstrate that the efflux transporter MRP3 plays an important role in resistance to sorafenib in HCC cells. (Tokushima University Institutional Repository) ● Metadata: 109929 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.6889 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26769852 ● Summary page in Scopus @ Elsevier: 2-s2.0-84981164782 (Tokushima University Institutional Repository: 109929, DOI: 10.18632/oncotarget.6889, PubMed: 26769852, Elsevier: Scopus)
31.	Jinsei Miyoshi, Hiroshi Miyamoto, Takahiro Goji, Tatsuya Taniguchi, Tetsu Tomonari, Masahiro Sogabe, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Yasuteru Fujino, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs., Journal of Gastroenterology and Hepatology, Vol.30, No.11, 1582-1590, 2015. (Summary) Objective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy. We prospectively enrolled 20 patients with unresectable metastatic gastric cancer who received oral S-1 (80 mg/m(2) ) on days 1-14, and intravenous cisplatin (60 mg/m(2) ) and docetaxel (50 mg/m(2) ) on day 8 every 3 weeks. Serum DAO activity was measured by colorimetry. Gastrointestinal toxicity was evaluated by CTCAE v4.0. Endoscopic examination and biopsy of duodenal mucosa assessed mucosal damage. Malnutrition was evaluated by measuring serum total protein and albumin levels. Serum DAO activity decreased step-by-step significantly during anticancer drug treatment and recovered after drug holidays. In all 14 patients who experienced diarrhea, serum DAO activity significantly decreased prior to diarrhea onset. Percent decrease in DAO activity was significantly correlated with severity of diarrhea. Significant correlation was observed between percent decrease in DAO activity and percent decrease in duodenal villus height or surface area from baseline. There were also significant correlations between percent decrease in serum DAO activity at day 14 and percent decrease in serum total protein or albumin levels at day 21 from baseline. Serum DAO activity sensitively indicates gastrointestinal damage prior to symptom onset and can be a useful predictor of intestinal mucosal damage and nutritional status in patients receiving chemotherapy. (Tokushima University Institutional Repository) ● Metadata: 109519 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.13004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25968084 ● Summary page in Scopus @ Elsevier: 2-s2.0-84943595915 (Tokushima University Institutional Repository: 109519, DOI: 10.1111/jgh.13004, PubMed: 25968084, Elsevier: Scopus)
32.	Masahiro Sogabe, Toshiya Okahisa, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Masahiko Nakasono and Tetsuji Takayama : Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome., Liver International, Vol.35, No.6, 1707-1714, 2015. (Summary) Although excess alcohol consumption has been believed to cause liver injury, light alcohol consumption (LAC) has been reported to play a protective role against fatty liver in recent studies. However, the association between non-alcoholic fatty liver disease (NAFLD) and LAC in men with metabolic syndrome (MS) is unclear. The aim of this study was to examine the association between NAFLD and LAC in men with MS. Subjects were 1055 men with MS who underwent a regular health check-up and drank less 20 g/day of alcohol. A distinction was made between non-drinkers and light drinkers and the association between NAFLD and LAC in men with MS was elucidated. NAFLD was referred as fatty liver with alanine aminotransferase (ALT) levels 31 IU/L in this study. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and the prevalence of NAFLD were significantly lower in light drinkers than in non-drinkers. Logistic regression analysis showed body mass index (BMI), waist circumference (WC), uric acid (UA), haemoglobin A1c (HbA1c), visceral fat type MS and LAC (odds ratios: 0.654; 95% confidence intervals: 0.473-0.906; <0.05) were significant predictors of the prevalence of NAFLD. The prevalence of NAFLD in light drinkers was significantly lower than in non-drinkers, and supporting previous reports studying the general population, LAC is one of the significant predictors of a decreased prevalence of NAFLD in men with MS. (Keyword) Abdomen / Adult / Aged / Alanine Transaminase / Alcohol Drinking / Asian Continental Ancestry Group / Aspartate Aminotransferases / Body Mass Index / Hemoglobin A, Glycosylated / Humans / Intra-Abdominal Fat / Japan / Logistic Models / Male / Metabolic Syndrome X / Middle Aged / Multivariate Analysis / Non-alcoholic Fatty Liver Disease / Odds Ratio / Surveys and Questionnaires / Uric Acid / Waist Circumference (Link to Publication Site) ● Publication site (DOI): 10.1111/liv.12754 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25438866 ● Search Scopus @ Elsevier (PMID): 25438866 ● Search Scopus @ Elsevier (DOI): 10.1111/liv.12754 (DOI: 10.1111/liv.12754, PubMed: 25438866)
33.	Hirao Akihiro, Tetsu Tomonari, Tanaka Hironori, Kumiko Tanaka, Kagawa Miwako, Tanaka Takahiro, Tatsuya Taniguchi, Harada Rie, Momoko Sato, Naoki Muguruma and Tetsuji Takayama : Development of a renal subcapsular hematoma during angiography for diagnosis and subsequent treatment of hepatocellular carcinoma, Clinical Journal of Gastroenterology, Vol.7, No.2, 185-188, 2014. (Summary) A renal subcapsular hematoma rarely occurs without a history of trauma. It has been reported as a complication of urological interventions and also reported to occur spontaneously in patients with renal malignancies. However, there are no previous reports of renal subcapsular hematomas occurring in connection with abdominal angiography. We report here a case of a renal subcapsular hematoma that developed and was recognized during abdominal angiography for treatment of hepatocellular carcinoma (HCC). An 80-year-old male was referred to our hospital for transarterial embolization for multiple HCCs. His past medical history included hypertension. His laboratory data showed slightly decreased number of platelets and hepaplastin test due to liver cirrhosis. When computed tomography angiography was performed, a 7-cm subcapsular hematoma developed and was recognized over the right kidney during the procedure. He was successfully managed supportively with blood transfusion, tranexamic acid and antibiotics. Since thrombocytopenia and hypertension are reportedly risk factors for hematoma formation, careful manipulation is required during angiography in HCC patients with liver cirrhosis and hypertension. It must be kept in mind that rare complications, such as a renal subcapsular hematoma, can happen during abdominal angiography for diagnostic and interventional treatment of HCC. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-014-0468-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26183639 ● Summary page in Scopus @ Elsevier: 2-s2.0-84900315664 (DOI: 10.1007/s12328-014-0468-4, PubMed: 26183639, Elsevier: Scopus)

Review, Commentary:

1.	Tetsu Tomonari : 新しい診断・薬の情報肝癌薬物療法における蛋白尿マネジメントと新規降圧剤円レスト®の位置付け., 肝臓クリニカルアップデート, Vol.9, No.1, 80-83, May 2023.
2.	Tetsu Tomonari : LAUNCH試験の結果とその解釈., KAN TAN SUI, Vol.85, No.3, 325-330, Sep. 2022.

Proceeding of International Conference:

1.	Hironori Tanaka, Tetsu Tomonari, Ryo Shinomiya, Mai Yonezawa, Yutaka Kawano and Tetsuji Takayama : Usefulness of shear wave elastography for evaluation of HCC recurrence after ablation., APASL2024, Kyoto, Mar. 2024.
2.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama : Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax Senticosus, ameliorates steatohepatitis in high-fat fed mice model., AASLD2023, Boston, Nov. 2023.
3.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama : Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax senticosus, ameliorates steatohepatitis in high-fat fed mice model., DDW2023, Chicago, May 2023.
4.	Tetsu Tomonari : WorkshopTreatment Strategy of Systemic drug Therapy for Intermediate Hepatocellular Carcinoma Aiming Curative Conversion Therapy., The Asian Pacific Association for the Study of the Liver (APASL Oncology 2022), Takamatsu, Sep. 2022.
5.	Toshiya Okahisa, Masahiro Sogabe, Ryosuke Ogata, Takatoshi Komatsu, Yoshiaki Ohnishi, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Yoshifumi Kida, Tetsu Tomonari, Hiroshi Miyamoto and Tetsuji Takayama : Concentration Ratio Self-regulation Function of Ascites Filtration and Concentration Equipment for Cell-free and Concentrated Ascites Reinfusion Therapy, ASAIO 67th Annual Conference, Chicago, Jun. 2022.
6.	Hironori Tanaka, Tetsu Tomonari, Reika Matsumoto, Kazuyoshi Noda, Tatsuya Taniguchi and Tetsuji Takayama : Usefulness of shear wave elastography for evaluation of hepatocellular carcinoma recurrence after ablation therapy., ACTA 2021(7th conference on Tumor Ablation), Oct. 2021.
7.	Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Hirao Akihiro, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Kagiwada Harumi, Kitazawa Masashi, Fukui Kazuhiko, Horimoto Katsuhisa and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array, ASCO Gastrointestinal Cancers Symposium(ASCO-GI 2020), San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.485 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.485 (DOI: 10.1200/JCO.2020.38.4_suppl.485)
8.	Naoki Muguruma, Fujimoto Daisaku, Yasuteru Fujino, Kashihara Takanori, Kazuyoshi Noda, Fukuya Akira, Takehara Masanori, Hirao Akihiro, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari and Tetsuji Takayama : Linked Color Imaging System in the Endoscopic Detection of Sessile Serrated Adenoma/Polyp, Korea International Digestive Endoscopy Congress 2019, Aug. 2019. (Keyword) Image-enhanced endoscopy / Linked color imaging / Sessile serrated adenoma/polyp
9.	Naoki Igata, J nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Drainage with Normal Saline in Two Directions for Washing of the Clogging Filter During Cell-free and Concentrated Ascites Reinfusion Therapy., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
10.	junji nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Development of Multiple Point Bowel-sound Analysis System (MPBAS) for the Optimization of the Bowel Sound Measurement Position., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
11.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma., digestive disease week2019, San Diego, May 2019.
12.	Jinsei Miyoshi, Noriaki Murayama, Kumiko Tanaka, Takahiro Tanaka, Fumika Nakamura, Yasuteru Fujino, Keiichiro Matsumura, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Development of a Novel Mirna-Based Signature to Predict Invasion and Metastasis in Rectal Neuroendocrine Tumors., digestive disease week2019, Vol.156, No.6, 133, San Diego, May 2019. (Link to Publication Site) ● Publication site (DOI): 10.1016/S0016-5085(19)37123-9 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/S0016-5085(19)37123-9 (DOI: 10.1016/S0016-5085(19)37123-9)
13.	Toshiya Okahisa, Masahiro Sogabe, Mayu Uyama, Tadahiko Nakagawa, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Takahiro Emoto, Masatake Akutagawa, M Yamada and M Fukuhara : Development Of A Multi-Ring Type Roller Pump Unit Equipped To A Compact And Convenient Ascites Purification Machine For Cell-Free And Concentrated Ascites Reinfusion Therapy (CART)., ASAIO 64th Annual Conference, Washington, D.C., Jun. 2018.
14.	Jinsei Miyoshi, Noriaki Murayama, Tadahiko Nakagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Mir-144-3P/451A as a Novel Biomarker for Predicting Recurrence and Metastasis in Rectal Neuroendocrine Tumors Through Targeting Pten/P19., Digestive Disease Week 2018, Washington, D.C., Jun. 2018.
15.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Noriaki Murayama, Masanori Takehara, Kaizo Kagemoto, Yoshifumi Takaoka, Tetsu Tomonari, Tatsuya Taniguchi, Tetsuo Kimura, Naoki Muguruma and Tetsuji Takayama : Influence of Lifestyle and Lifestyle-Related Disease on Nonalcoholic Fatty Liver Disease in Japanese With Metabolic Syndrome, Digestive Disease Week2016, San Diego, May 2016.
16.	Tatsuya Taniguchi, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Tadahiko Nakagawa and Tetsuji Takayama : Des-g-carboxy Prothrombin (DCP) Is Produced by Overexpression of Prothrombin Gene in Hepatocellular Carcinoma, Digestive Disease Week2016, San Diego, May 2016.
17.	Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : MRP3 As a Novel Resistance Factor for Sorafenib in Hepatocellular Carcinoma, Digestive Disease Week2016, San Diego, May 2016.
18.	Tatsuya Taniguchi, Tetsu Tomonari and Tetsuji Takayama : Des-γ-carboxy prothrombin (DCP) producing mechanism based on PARP-1 in hepatocellular carcinoma, 第23回消化器関連学会週間, Tokyo, Oct. 2015.
19.	Tatsuya Taniguchi, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa and Tetsuji Takayama : Des-G-Carboxy Prothrombin (DCP) Is Induced by PARP-1 in Hepatocellular Carcinoma, Digestive Disease Week 2015, Washington, D.C., May 2015.
20.	Kagawa Miwako, Toshiya Okahisa, Takaoka yoshifumi, Yasuteru Fujino, Jinsei Miyoshi, Takaoka Toshi, Tetsu Tomonari, Shinji Kitamura, Okada Yasuyuki, Kagemoto Kaizo, Takehara Masanori, Kumiko Tanaka, Matsumoto Sayo, Teramae Tomofumi, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama and Takaoka Toshi : Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage, Digestive Disease Week2014, Chicago, May 2014.
21.	Hidetaka Takenaka, Katsuyoshi Tamaki, Tatsuya Taniguchi, Tetsu Tomonari, Rie Harada, Katsutaka Sannomiya, Momoko Sato, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Radiofrequency ablation using a balloon catheter for hepatocellular carcinoma adjacent to the gastrointestinal tract:Experimental and Clinical Study, Digestive Disease Week 2011, Chicago, Chicago, May 2011.
22.	Masako Kaji, Tetsu Tomonari, Kagawa Miwako, Saito Azusa, Tsuda Miho, Harada Rie, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Niki Miyako, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Usefulness of electrocolonography for evaluation of colonic motility, Digestive Disease Week 2010, New Orleans, May 2010.
23.	Toshiya Okahisa, Tsuda Miho, Tetsu Tomonari, Inoue Atsushi, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Takeuchi Hisashi, Koichi Okamoto, Niki Miyako, Masako Kaji, Seisuke Okamura, Kanno Ryota, Shinsuke Konaka, Takahiro Emoto, Masatake Akutagawa and Tetsuji Takayama : Vascular patterns assessed by vascular analysis software are predictive of relapse in patients with inactive ulcerative colitis, Digestive Disease Week 2010, New Orleans, May 2010.

Proceeding of Domestic Conference:

1.	Yutaka Kawano, Tetsu Tomonari, Yasushi Sato and Tetsuji Takayama : MAFLD/MASHマウスモデルを用いたフィトケミカル含有食品エゾウコギの基礎検討., 第42回Cytoprotection研究会, Mar. 2024.
2.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 切除不能肝細胞癌に対するAblationを用いたConversion therapyの有効性-治療後経過や長期成績について., 第2回アブレーション研究会, Feb. 2024.
3.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Yutaka Kawano, 森下朝洋, 正木勉 and Tetsuji Takayama : 切除不能肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績., 第29回日本肝がん分子標的治療研究会, Jan. 2024.
4.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 切除不能肝細胞癌に対するlater line症例を含むデュルバルマブ+トレメリムマブ併用療法の初期治療成績., 第45回日本肝臓学会西部会, Dec. 2023.
5.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌局所穿刺療法困難症例に対する定位放射線療法の治療成績., 第45回日本肝臓学会西部会, Dec. 2023.
6.	Tetsu Tomonari, Yasuyuki Okada, Hiroshi Miyamoto and Tetsuji Takayama : 膵腫瘍に対するがん遺伝子パネル検査を念頭に置いたEUS-FNAの至適な方法についての検討., JDDW2023, Nov. 2023.
7.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : MR Elastography によるNAFLDの肝線維化評価., JDDW2023, Nov. 2023.
8.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 切除不能肝細胞癌に対する薬物療法を用いたConversion therapyの有用性-治療後経過や長期成績について-., JDDW2023, Nov. 2023.
9.	Yutaka Kawano, 渡邉奈々恵, 西山正彦, 小野薫, Yasushi Sato, 照井健, 日下部俊郎, Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : がん関連疲労に対するエゾウコギ含有食品の実行可能性試験., 第 61 回日本癌治療学会学術集会, Oct. 2023.
10.	MATSUMOTO Rikizo, Susumu Nishio, Sae Morita, Asami Yuasa, Yukina Hirata, Yu Saitou, Tetsu Tomonari, Takeshi Oya, Yoshimi Bando and Masataka Sata : 術前診断が困難であった肝臓原発リンパ管腫の1例, 第33回日本超音波産学会四国地方会学術集会, Oct. 2023.
11.	MATSUMOTO Rikizo, Susumu Nishio, Sae Morita, Asami Yuasa, Yukina Hirata, Yu Saitou, Tetsu Tomonari, Takeshi Oya, Yoshimi Bando and Masataka Sata : 術前診断が困難であった肝臓原発リンパ管腫の1例, 第33回日本超音波産学会四国地方会学術集会, Oct. 2023.
12.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌に対する定位放射線療法の治療成績., 第59回日本肝癌研究会, Jul. 2023.
13.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 根治的Combination Therapyを見据えた肝癌薬物療法の治療戦略., 第59回日本肝癌研究会, Jul. 2023.
14.	Tetsu Tomonari, Hironori Tanaka, Yutaka Kawano, Yasushi Sato and Tetsuji Takayama : デュルバルマブ+トレメリムマブ併用療法を見据えた肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療戦略., 第28回日本肝がん分子標的治療研究会, Jun. 2023.
15.	Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : 肝細胞癌に対する定位放射線療法の治療成績., 第59回日本肝臓学会総会, Jun. 2023.
16.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 切除不能進行肝癌に対する薬物療法を用いた Coversion therapy の治療成績―レンバチニブ及びアテゾリズマブ+ベバシズマブ併用療法を用いた比較検討―., 第59回日本肝臓学会総会, Jun. 2023.
17.	Tetsu Tomonari, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Hiroshi Miyamoto and Tetsuji Takayama : 悪性肝腫瘍に対するEmprint Ablation Systemの治療成績., 日本超音波医学会第96回学術集会, May 2023.
18.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 高リスク食道静脈瘤の評価におけるMR Elastographyの有用性., 第109回日本消化器病学会総会, Apr. 2023.
19.	平田圭市郎, Hiroyuki Ueda, takanori miyake, takanori kashihara, Yasuyuki Okada, Hironori Tanaka, hironori wada, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Hitoshi Ikushima, Yoshimi Bando, Yasushi Sato and Tetsuji Takayama : 切除不能・再発膵神経内分泌腫瘍(pancreatic neruoendocrine neoplasm:P-NEN)に対する集学的治療による治療成績の向上., 第109回日本消化器病学会総会, Apr. 2023.
20.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Tsutomu Masaki and Tetsuji Takayama : アテゾリズマブ+ベバシズマブ，レンバチニブを用いた切除不能肝細胞癌に対する根治的Conversion therapyの治療成績., 第20回日本臨床腫瘍学会学術集会, Mar. 2023.
21.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Tatsuya Taniguchi, 正木勉 and Tetsuji Takayama : 切除不能進行肝癌に対するAblationを用いたCenversion療法の可能性., 第1回日本アブレーション研究会, Feb. 2023.
22.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : Shear wave elastgraphyによる肝細胞癌焼灼術後の再発リスク評価., 第1回日本アブレーション研究会, Feb. 2023.
23.	Tetsu Tomonari, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano and Tetsuji Takayama : 切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法後のレンバチニブ及び根底的Conversion治療の有効性., 第27回日本肝がん分子標的治療研究会, Jan. 2023.
24.	Takero Kawashima, Shunto Kataoka, Ryo Takue, Hideo Suzuki, 緒方良輔, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe, Hiroyuki Ueda and Toshiya Okahisa : 胸腹水濾過濃縮時の濃縮圧の自動制御に関する実験的検討., 第60回日本人工臓器学会大会, Nov. 2022.
25.	Shunto Kataoka, Takero Kawashima, Ryo Takue, Hideo Suzuki, 緒方良輔, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Hiroyuki Ueda : 胸腹水濾過濃縮時の目詰まり濾過器の洗浄法の最適化に関する実験的検討., 第60回日本人工臓器学会大会,, Nov. 2022.
26.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : Shear wave elastographyによる肝細胞癌焼灼術後の再発リスク評価., JDDW2022(第30回日本消化器関連学会週間), Oct. 2022.
27.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : 根治的Combination therapyを見据えた肝癌薬物療法の治療戦略., JDDW2022(第30回日本消化器関連学会週間), Oct. 2022.
28.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 正木勉 and Tetsuji Takayama : 肝癌薬物療法における根治的Combination therapyの有効性, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
29.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : Conversion治療及びSequential療法を見据えた肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法の治療戦略., 第58回日本肝臓学会総会, Jun. 2022.
30.	Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : NAFLD/NASHの線維化評価におけるME Elastographyの有用性., 第58回日本肝臓学会総会, Jun. 2022.
31.	中村昌史, Hirokazu Miki, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋朋子, 高橋真美子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, 西尾進, Tetsu Tomonari and Masahiro Abe : ALアミロイドーシスの肝病変の評価における超音波エラストグラフィの有用性, The Japanese Journal of Clinical Hematology, Vol.63, No.6, 685-686, Jun. 2022. (Keyword) 肝臓疾患(超音波診断,薬物療法) 組織弾性イメージング *アミロイドーシス-免疫グロブリン軽鎖(超音波診断,薬物療法) ヒト中年(45∼64) 男女
32.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対する根治的Combination therapyの有効性., 第58回日本肝癌研究会, May 2022.
33.	Tetsu Tomonari, 谷丈二 and Tetsuji Takayama : Cancer free及びSequential治療を見据えたアテゾリズマブ・ベバシズマブ療法の治療戦略., 第58回日本肝癌研究会, May 2022.
34.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Naoki Muguruma, Kensei Nishida and Tetsuji Takayama : 肝細胞癌においてmiR-125b-5pは上皮間葉転換を引き起こし，ソラフェニブに対して耐性を獲得する, 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
35.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝洋, Yasushi Sato, 正木勉 and Tetsuji Takayama : 後治療を見据えた肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療戦略., 第25回日本肝がん分子標的治療研究会, Jan. 2022.
36.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝洋, 正木勉 and Tetsuji Takayama : 薬物療法既治療例を含む切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療成績., JDDW2021(第29回日本消化器医関連学会週間), Nov. 2021.
37.	Hironori Tanaka, Tetsu Tomonari, kaizo kagemoto, Yasuyuki Okada, hironori wada, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 免疫チェックポイント阻害薬投与中の肝障害., 第59回日本癌治療学会学術集会, Oct. 2021.
38.	Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, 中村昌史, 水口槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋真美子, 丸橋朋子, Takeshi Harada, Kumiko Kagawa, Nishio Susumu, Tetsu Tomonari and Masahiro Abe : 肝臓アミロイドーシスに対する超音波エラストグラフィの診断的有用性., 第83回日本血液学会学術集会, OS1-8D-2, Sep. 2021.
39.	Rei Mizobuchi, Hironori Tanaka, Naoya Tani, Kazuyoshi Noda, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Tomomi Matsuura, Masataka Sata and Tetsuji Takayama : 超音波観察を併用することで安全に治療した高度腎機能低下を合併した猪瀬型肝性脳症の1例, 第263回徳島医学会学術集会, Aug. 2021.
40.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝弘, 正木勉 and Tetsuji Takayama : 薬物療法既治療例を含む切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療成績., 第24回日本肝がん分子標的治療研究会, Aug. 2021.
41.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : Therapeutic strategy of lenvatinib for hepatocelluar carcinoma in intermediate-stage., 第57回日本肝癌研究会, Jul. 2021.
42.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の薬物療法既治療例を含む初期治療成績., 第57回日本肝臓学会総会, Jun. 2021.
43.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi and Tetsuji Takayama : 肝細胞癌焼灼術後の再発リスク評価における超音波エラストグラフィの有用性, 日本超音波医学会第94 回学術集会, May 2021.
44.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 高リスク食道胃静脈瘤の評価におけるMR Elastographyの有用性., 第107回日本消化器病学会総会, Apr. 2021.
45.	Yu Saitou, Tetsu Tomonari, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療 - 分子標的治療薬使用によるConversion Surgery –, 第121回日本外科学会定期学術集会, Apr. 2021.
46.	石田卓也, Hirokazu Miki, 髙橋真美子, 中村昌史, 水口槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋朋子, 岡本秀樹, Naoto Okada, 矢野由美子, 高橋真理, Tetsu Tomonari, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Keiko Aota, Hiroyoshi Watanabe and Masahiro Abe : HIV感染血友病患者における臨床的特徴と今後の課題, 第262回徳島医学会学術集会, Mar. 2021.
47.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yuji Morine, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療-分子標的治療薬使用によるConversion Surgery-, 第23回日本肝がん分子標的治療研究会, Jan. 2021.
48.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 悪性肝腫瘍に対するEmprint Ablation Systemの治療成績-多血肝細胞癌の肝動脈塞栓術併用療法を中心にー, 第56回日本肝癌研究会, Dec. 2020.
49.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対するLenvatinib治療後のSorafenib, Ramucirumabの治療成績., 第22回日本肝がん分子標的治療研究会, Nov. 2020.
50.	Naoki Igata, 緒方良輔, 佐藤翔平, 坂東直紀, 小松崇俊, 小林誠司, 大西芳明, 田中克哉, 福原正史, Tadahiko Nakagawa, Kumiko Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 腹水濾過濃縮再静注法施行時の濃縮器の目詰まり対策., 第58回日本人工臓器学会大会, Nov. 2020.
51.	Tadahiko Nakagawa, Sayaka Takeuchi, Haruki Yamada, Naoki Igata, 板東直紀, 緒方良輔, 佐藤翔平, Tetsu Tomonari, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 胸腹水の循環式濾過濃縮処理時の物理刺激によるサイトカイン濃度の上昇., 第58回日本人工臓器学会大会, Nov. 2020.
52.	山田青季, 井形直紀, 竹内彩郁薫, 多田理香, 緒方良輔, 佐藤翔平, 坂東直紀, Yoshiaki Ohnishi, Masaki Oono, Masami Shishibori, Masao Fuketa, Kenji Terada, Kumiko Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 腹水濾過濃縮再静注法の圧力シート., 第58回日本人工臓器学会大会, Nov. 2020.
53.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌におけるLenvatinibを用いたConversion therapyの治療成績., 第28回消化器関連学会週間(JDDW2020), Nov. 2020.
54.	佐藤翔平, 緒方良輔, 坂東直紀, 小松崇俊, 小林誠司, Yoshiaki Ohnishi, Katsuya Tanaka, 福原正史, Tadahiko Nakagawa, 井形直紀, Kumiko Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 胸腹水濾過濃縮時のM-CARTによる濃縮倍率の自動調整., 第41回日本アフェレシス学会学術大会, Oct. 2020.
55.	横山怜子, Fumika Nakamura, Yasushi Sato, Kazuhiro Kishi, 和田浩典, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : 胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響., 第58回日本癌治療学会学術集会, Oct. 2020.
56.	Tetsu Tomonari, Yasushi Sato and Tetsuji Takayama : レンバチニブのソラフェニブ既治療肝癌に対する有効性の検討ー実臨床データとプロテインアレイ解析ー., 第56回日本肝臓学会総会, Aug. 2020.
57.	Tetsu Tomonari, Yasushi Sato and Tetsuji Takayama : ソラフェニブ既治療肝癌に対するレンバチニブの治療効果の検討―実臨床データとプロテインアレイ解析―., 第106回日本消化器病学会総会, Aug. 2020.
58.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Tetsuji Takayama and Mitsuo Shimada : 分子標的治療薬によりConversion Hepatectomyを施行し得た進行肝細胞癌の3例, 第21回日本肝がん分子標的治療研究会, Jan. 2020.
59.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yu Saitou, Satoru Imura, Mitsuo Shimada and Tetsuji Takayama : 進行肝癌におけるLenvatinibを用いたConversion Therapyの可能性―肝切除, Microwave ablation, 肝動脈塞栓術による追加治療の検討―., 第21回日本肝がん分子標的治療研究会, Jan. 2020.
60.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 進行肝癌におけるレンバチニブの最適な投与タイミングの検討., JDDW2019(第27回日本消化器関連学会週間), Nov. 2019.
61.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 免疫チェックポイント阻害薬による肝障害―作用機序との関連についてー., JDDW2019(第27回日本消化器関連学会週間), Nov. 2019.
62.	Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
63.	Jinsei Miyoshi, 村山典聡, Satoshi Teramae, 宮本佳彦, Hironori Tanaka, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Takahiro Tanaka, Kumiko Tanaka, 松村圭一郎, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 直腸NETのmicroRNA網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
64.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 進行肝癌に対するレンバチニブの治療経過における肝予備能の推移., 日本肝がん分子標的治療研究会, Jun. 2019.
65.	Tetsu Tomonari, Takahiro Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対するレンバチニブの有効性と安全性の検討., 第55回日本肝臓学会総会, May 2019.
66.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 免疫チェックポイント阻害薬による肝胆道障害の検討., 第55回日本肝臓学会総会, May 2019.
67.	Tetsu Tomonari, Takahiro Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対するレンバチニブの有効性と安全性の検討., 第105回日本消化器病学会総会, May 2019.
68.	Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対する分子標的治療薬の有害事象プロファイル―Sorafenib, Regorafenib, Lenvatinibの比較―, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
69.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 実臨床におけるLenvatinibの使用経験, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
70.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 肝細胞癌に対する肝動脈塞栓術併用Emprint Ablation Systemの治療成績., 第42回日本肝臓学会東部会, Dec. 2018.
71.	Naoki Igata, Kazuhide Iwasa, Junji Nishioka, Tetsuya Honda, Kazuyoshi Noda, Yoshifumi Kida, Tatsunao Sueuchi, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 腹水濾過濃縮再静注法(CART)の濾過濃縮処理による腹水中物質の濃度変化., 第56回日本人工臓器学会大会, Nov. 2018.
72.	西岡潤司, 水谷太郎, 井形直紀, 岩佐一秀, 本多哲也, Kazuyoshi Noda, 高岡慶史, Tatsunao Sueuchi, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Multiple Point Bowel-sound Analysis System(MPBAS)の試作による腸蠕動音測定部位の最適化, 第56回日本人工臓器学会大会, Nov. 2018.
73.	Tetsu Tomonari and Tetsuji Takayama : 切除不能進行肝癌におけるRegorafenib有効症例の検討., 第26回日本消化器関連学会週間(第22回日本肝臓学会大会), Nov. 2018.
74.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : MR Elastographyによる食道胃静脈瘤の治療適応評価., 第26回日本消化器関連学会週間, Nov. 2018.
75.	Tetsu Tomonari, Yoshihiko Miyamoto, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 集学的治療奏功例を含む進行肝癌に対する Regorafenib の初期治療成績., 第18回日本肝がん分子標的治療研究会, Jul. 2018.
76.	Tetsu Tomonari, 新居徹, 津保友香, Yoshihiko Miyamoto, Hironori Tanaka, Takahiro Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 集学的治療奏功例を含む進行肝癌に対するRegorafenibの初期治療成績., 第54回日本肝癌研究会, Jun. 2018.
77.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌に対するミリプラチン併用化学放射線療法の検討., 第54回日本肝臓学会総会, Jun. 2018.
78.	Tetsu Tomonari, 平尾章博 and Tetsuji Takayama : 切除不能進行肝細胞癌の MRP3 発現に基づく個別化治療戦略., 第104回日本消化器病学会総会, Apr. 2018.
79.	Yasuteru Fujino, 池田敬洋, Tetsu Tomonari, Yasuhiro Mitsui, 香川美和子, Momoko Sato, 仁木美也子, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Ipilimumab にて完全奏功が得られた転移性直腸悪性黒色腫の1例., 第 55 回日本癌治療学会学術集会,, Oct. 2017.
80.	Tetsu Tomonari, Takahiro Tanaka and Tetsuji Takayama : MRP3発現に基づく切除不能進行肝細胞癌の個別化治療, 第25回日本消化器関連学会週間(JDDW2017), Oct. 2017.
81.	Tetsu Tomonari, Takahiro Tanaka and Tetsuji Takayama : MRP3発現に基づく切除不能進行肝細胞癌の治療戦略., 第53回日本肝臓学会総会, Jun. 2017.
82.	田中貴大, Tetsu Tomonari, Tetsuji Takayama, 栗原健士, 岡田怜子, 福家慧, 平尾章博, 田中宏典 and Tatsuya Taniguchi : Direct-acting antivirals(DAAs)による慢性C型肝炎治療後の発癌予測因子の検討, 第103回日本消化器病学会総会, Apr. 2017.
83.	Mayu Uyama, Masahiro Sogabe, Toshiya Okahisa, 平田光里, Tadahiko Nakagawa, 村山典聡, 武原正典, 松本友里, 岡崎潤, 高岡慶史, Yasuteru Fujino, 香川美和子, 田中貴大, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 胸腹水濾過濃縮再静注法の施行状況と今後の課題, 第37会日本アフェレシス学会学術大会, Nov. 2016.
84.	Ryuto Tamai, Hiroto Kasai, Daiki Tanaka, Naoya Tani, 平田光里, Tadahiko Nakagawa, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Tetsuji Takayama, Takahiro Emoto, Masatake Akutagawa, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Mayu Uyama, Masahiro Sogabe and Toshiya Okahisa : 胸腹水濾過濃縮再静注法のクロスフロー方式の腹水濾過時の物理的刺激が腹水に及ぼす影響に関する実験的検討., 第54回日本人工臓器学会大会, Nov. 2016.
85.	田中宏典, Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : MPR3発現に基づく切除不能進行肝細胞癌の個別化治療, 第52回日本肝臓学会総会, May 2016.
86.	Daiki Tanaka, Naoya Tani, Masanori Takehara, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Tadahiko Nakagawa, Tetsuji Takayama, Masaki Kawano, Takahiro Emoto, Masatake Akutagawa, Yohsuke Kinouchi, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Mayu Uyama, Masahiro Sogabe and Toshiya Okahisa : 模擬腹水を用いた胸腹水濾過濃縮装置の評価・教育システムの構築, 第53回日本人工臓器学会大会, Nov. 2015.
87.	宇山真由, Masahiro Sogabe, Toshiya Okahisa, 中川忠彦, 武原正典, 高岡慶史, 香川美和子, 田中貴大, Tetsu Tomonari, Tatsuya Taniguchi, Tetsuo Kimura and Tetsuji Takayama : 徳島県における胸腹水濾過濃縮療法(CART)の現状と課題, 第36回日本アフェレシス学会学術大会, Oct. 2015.
88.	Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : MRP3発現に基づく切除不能進行肝細胞癌の個別化治療., 第23回消化器関連学会週間(第57回日本消化器病学会大会), Oct. 2015.
89.	Kumiko Tanaka, Naoki Muguruma, 岡崎潤, 岡田泰行, 高岡慶史, 田中宏典, 宮本佳彦, 松本早代, 田中貴大, Yasuteru Fujino, 香川美和子, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Toshiya Okahisa, 石川秀樹 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変の検討 -形態学的，病理組織学的解析を含めて-, 第23回消化器関連学会週間(第57回日本消化器病学会大会), Oct. 2015.
90.	田中貴大, 影本開三, 田中宏典, Tatsuya Taniguchi, Tetsu Tomonari, 中川忠彦, Kazuhiro Kishi and Tetsuji Takayama : PIVKA-II 産生肝細胞癌におけるPARP-1 発現の意義とPARP-1 を標的とした新しい個別化治療薬の検討, 第51回日本肝臓学会総会, May 2015.
91.	Tetsu Tomonari, Tatsuya Taniguchi, Masahiro Sogabe, 影本開三, 岡田泰行, 田中宏典, 田中貴大, Toshiya Okahisa and Tetsuji Takayama : 肝細胞癌に対する球状塞栓物質を用いた肝動脈化学塞栓療法の有用性., 第51回日本肝臓学会総会, May 2015.
92.	Tatsuya Taniguchi, 田中貴大, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌におけるPIVKA-Ⅱ産生機序の解析 ―PARP-1による発現の誘導―, 第18回日本肝臓学会大会, Oct. 2014.
93.	中川忠彦, 田中宏典, 岡崎潤, Kumiko Tanaka, 田中貴大, 髙岡遠, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Tetsuji Takayama, Masahiro Sogabe, Takahiro Emoto, Masatake Akutagawa, Hiroshi Shibata, 矢野充保, 岸史子, 大喜田義雄, 山路諭, 田中善二 and Toshiya Okahisa : 腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響, 第35回日本アフェレシス学会学術大会, Sep. 2014.
94.	Tatsuya Taniguchi, 影本開三, 田中宏典, 田中貴大, Tetsu Tomonari, 三宮勝隆, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 肝細胞癌におけるPIVKA-Ⅱの発現機序の解明―PARP1の役割―, 第73回日本癌学会学術総会, Sep. 2014.
95.	田中貴大, Tatsuya Taniguchi, 高岡慶史, 岡崎潤, 田中宏典, 大塚加奈子, Tetsu Tomonari, 原田利枝, Momoko Sato and Tetsuji Takayama : 肝性腹水におけるトルバプタン不応症例の検討, 第50回日本肝臓学会総会, May 2014.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

プロテインアレイを用いた肝細胞癌に対するレンバチニブの新たなバイオマーカーの解明 (Project/Area Number: 21K07964 )
Evaluation of biomarkers based on metabolome analysis of sorafenib-resistant hepatocellular carcinoma (Project/Area Number: 18K15816 )
Establishment and mechanism of sorafenib-resistant cells (Project/Area Number: 15K19331 )
Search by Researcher Number (20556807)

Associate Professor : Tomonari, Tetsu

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)